{"nctId":"NCT00639158","briefTitle":"Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood","startDateStruct":{"date":"2008-02"},"conditions":["Dyslipidemias","Coronary Heart Disease","Combined (Atherogenic) Dyslipidemia","Mixed Dyslipidemia"],"count":543,"armGroups":[{"label":"ABT-335 + atorvastatin + ezetimibe","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: atorvastatin","Drug: ezetimibe"]},{"label":"Placebo + atorvastatin + ezetimibe","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo","Drug: atorvastatin","Drug: ezetimibe"]}],"interventions":[{"name":"ABT-335","otherNames":["TriLipix","Fenofibric acid","Choline Fenofibrate"]},{"name":"placebo","otherNames":[]},{"name":"atorvastatin","otherNames":["Lipitor"]},{"name":"ezetimibe","otherNames":["Ezetrol","Zetia","Ezemibe"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with mixed dyslipidemia (trigylcerides, \\> or = to 150 mg/dL to \\< 400 mg/dL; HDL-C \\< 40 mg/dL for males, \\< 50 mg/dL for females; LDL-C, \\> or = to 130 mg/dL).\n* Subjects must agree to use adequate birth control methods and to adhere to the American Heart Association (AHA) Diet.\n\nExclusion Criteria:\n\n* Subjects with unstable or uncontrolled medical conditions considered inappropriate in a clinical trial.\n* Subjects with an unstable dose of medications or receiving Coumadin, oral, intravenous or intramuscular cyclosporine, statins, or certain other medications.\n* Women who are pregnant or plan on becoming pregnant, or women who are lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Median Percent Change in Triglycerides From Baseline to Final Visit","description":"\\[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides\\] x 100","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.3","spread":"22.32"},{"groupId":"OG001","value":"-39.7","spread":"29.44"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit","description":"\\[(Week 12 apoAI minus baseline apoAI)/baseline apoAI\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.74"},{"groupId":"OG001","value":"-1.3","spread":"0.76"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit","description":"\\[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"0.95"},{"groupId":"OG001","value":"4.2","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit","description":"\\[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.8","spread":"1.87"},{"groupId":"OG001","value":"-41.1","spread":"1.87"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit","description":"\\[(Week 12 apoCIII minus baseline apoCIII)/baseline apoCIII\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.5","spread":"1.22"},{"groupId":"OG001","value":"-25.3","spread":"1.23"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit","description":"\\[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.6","spread":"0.94"},{"groupId":"OG001","value":"-51.0","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit","description":"\\[(Week 12 apoB minus baseline apoB)/baseline apoB\\] x 100","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.1","spread":"0.91"},{"groupId":"OG001","value":"-44.7","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit","description":"\\[(Week 12 hsCRP minus baseline hsCRP)/baseline hSCRP\\] x 100","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.1","spread":"102.82"},{"groupId":"OG001","value":"-40.3","spread":"516.56"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":272},"commonTop":["Muscle Spasms","Myalgia","Arthralgia","Fatigue","Diarrhea"]}}}